Methods: We recruited white, nondiabetic men into a crosssectional substudy of a larger cohort including 3 demographically matched groups. Optic disc-centered 45-degree color fundus photographs were used to calculate central retinal arterial and venous caliber and the arterial-venous ratio (AVR). We used univariate and multivariable linear regression to compare retinal vessel measurements in the 3 groups and to identify factors associated with AVR. Conclusions: There were no differences in retinal vascular indices between HIV-positive men aged $50 years and HIV-negative men aged $50 years or HIV-positive men aged ,50 years, suggesting that HIV is not associated with an increased burden of cerebral small vessel disease.
INTRODUCTION
Life expectancy of people living with HIV (PLWH) now approaches that of the general population in many countries, 1 and an increasing proportion of PLWH is older than the age of 50 years. 2, 3 As the cohort ages, PLWH are at a greater risk of comorbidities of older age such as cardiovascular disease, dementia, hypertension, and type 2 diabetes. Cerebral small vessel disease (SVD) is associated with circulating inflammatory mediators and chronic immune activation in HIV-negative populations. 4, 5 Corresponding elevations of systemic inflammatory markers are reported in HIV even after virological suppression has been achieved. 6, 7 It is plausible that HIV infection in middle and older age is associated with an increased risk of cerebral SVD. Cognitive impairment is reported to be highly prevalent in PLWH, [8] [9] [10] and SVD is one potential mechanism for this.
Although epidemiological evidence suggests higher rates of large vessel ischemic stroke in PLWH, [11] [12] [13] [14] [15] [16] [17] [18] SVD is likely to involve different pathological processes, and there have been fewer studies of SVD in HIV. One study of Dutch HIV-positive men aged older than 45 years, and HIVnegative controls reported a greater burden of white matter hyperintensities of presumed vascular origin on brain magnetic resonance imaging, 19 whereas 2 similar studies have found no association between HIV and neuroimaging measures of SVD, 20, 21 and an autopsy study of SVD found similar negative results. 22 The retina shares common embryological and physiological features with the central nervous system, and retinal vascular photography provides a cheaper, quicker, and noninvasive way of indirectly measuring SVD. In cross-sectional studies in the general HIV-negative population, retinal vascular abnormalities (measured quantitatively by vessel diameters or qualitatively by retinopathy) have been found to be independently associated with the extent of white matter hyperintensities 23, 24 and the presence of dementia in people with hypertension. 25 In cohorts, similar markers are independently associated with progression of cerebrovascular SVD 26 and ventricular enlargement. 27 All these neuropathological phenomena are associated with vascular cognitive impairment.
To date, one published study has compared retinal vascular measures between PLWH and HIV-negative controls. 28 The study was conducted in Cape Town, South Africa and recruited mainly young adult Xhosa women (75% women, median age 40 years, 19% of the study sample aged older than 50). There were no overall differences in arteriolar or venular diameter between PLWH and controls. A US-based study also looked at retinal measures in PLWH but did not include a seronegative control group. 29 There is a need for studies using retinal vascular measurements in other ethnic groups and in older, male participants who make up a larger proportion of PLWH in high-income countries and who are potentially at the greatest risk of SVD. This study aimed to determine the association between HIV status, age, and retinal vascular measurements in a UKbased sample of men living with HIV aged 50 years and older, and comparable groups of HIV-negative men of similar age and HIV-positive men aged younger than 50 years.
METHODS

Study Population
We conducted a cross-sectional ophthalmic substudy within the Pharmacokinetic and Clinical Observations in People over 50 (POPPY) study, a multicentre UK and Ireland cohort study exploring a range of age-associated measures of health, service use, and pharmacokinetic parameters in PLWH (ClinicalTrials.gov Identifier: NCT01737047). POPPY comprises 3 demographically matched groups (PLWH aged $50 years; PLWH aged ,50 years; HIV-negative persons aged $50 years) in a 2:1:1 ratio and includes both white and black African participants. White, male, nondiabetic participants were recruited between May 2014 and July 2016 in London and Brighton, and the United Kingdom in the same proportions as the parent cohort. Participants gave written, informed consent, and the study was approved by the National Research Ethics Service Committee London-Camden & Islington, reference 14/LO/0316. Sample size calculations were based on observations from a previous study, 28 where the arteriolar diameter in participants older than 50 years was a mean of 159.13, SD of 17.63 in PLWH, and a mean of 166.24, SD 18.56 in HIVnegative participants. Assuming that similar differences existed in the target population, and maintaining the 2:1:1 ratio, we aimed to include 156 HIV-positive men aged $50 years and 78 in each of the other 2 groups. This would achieve 80% power and an alpha level of 5% (STATA Statistics and Data Analysis software version 14.1; StataCorp, College Station, TX).
Data Collection
Optic disc-centered 45-degree color fundus photographs were taken at 3 study sites and uploaded to a central site (Moorfields Eye Hospital). In the first instance, this was performed with undilated pupils, and image quality was assessed in real time to determine the need for tropicamideinduced dilatation and repeat photography. Techniques for measurement and calculation of central retinal artery equivalent (CRAE) and central retinal vein equivalent (CRVE) and the arterial-venous ratio (AVR) have been reported previously. 30, 31 Diameters of all vessels crossing a zone of 0.5-1 disk diameter from the disk margin were assessed by the same certified and validated grader using image analysis software. The calibers of the 6 largest arterioles and the 6 largest venules were combined to estimate the caliber of the central retinal artery and vein. The AVR, a ratio of these 2 measures, was calculated for each eye.
The POPPY cohort database provided clinical information relating to previous cardiovascular disease and risk factors, current and previous antiretroviral therapy use, latest CD4 + and CD8 + lymphocyte counts, anthropometric data, syphilis and hepatitis C virus serology, recreational drug use, and serum lipids. Framingham 10-year cardiovascular disease risk was calculated using the Framingham STATA module. 32, 33 
Statistical Analysis
After excluding images of insufficient quality, retinal measurements from one randomly chosen eye per participant were compared between the 3 groups (HIV positive $50, HIV positive ,50, and HIV negative $50) using linear regression. PLWH who did not have a suppressed HIV-1 viral load (,50 copies/mL) on antiretroviral therapy were excluded from the analysis. Factors associated with AVR were determined in bivariate models. Variables considered included study group as 3 categories, linear continuous variables (body mass index, waist circumference, diastolic and systolic blood pressure (BP), and concentrations of total, high density lipoprotein, and low density lipoprotein cholesterol) and binary variables [smoking status, self-reported history of ischemic heart disease, stroke or transient ischemic attack (TIA), injection drug use, psychoactive recreational drug use in the past 6 months, hepatitis C antibody status, and previous syphilis]. Study group and factors found to have at least a modest association (P , 0.2) with AVR in bivariate models were analyzed in multivariable linear regression models.
Additional linear regression analyses including only HIV-positive participants explored associations between AVR and HIV-specific factors (linear continuous variables of CD4 + and CD8 + lymphocyte counts and CD4:CD8 ratio, time since HIV diagnosis, time between diagnosis and first initiation of antiretroviral therapy, and total duration of antiretroviral therapy, and binary categorization of current use of all antiretroviral drug classes as well as abacavir and tenofovir), adjusted for study group (older or younger than 50 years). Again, a multivariable model was constructed of all variables found to be at least weakly associated (P , 0.2) with AVR in bivariate models.
RESULTS
Participant Characteristics
In total, 228 people were photographed. Of these, grading was successfully performed on photographs from 211 participants (411 eyes; 120 HIV positive aged $50 years; 39 HIV positive ,50 years; and 52 HIV negative $50 years). Reasons for exclusion of the other 17 were missing data (n = 6), incorrect field definition used during photography (n = 8), photographs too dark (n = 2), and severe tilting of the optic disc (n = 1).
There were some differences between the 3 groups, such as a higher rate of current smoking in PLWH aged ,50, more PLWH reporting a lifetime history of injection drug use, and more PLWH in the older group reporting a history of stroke or TIA, or being seropositive for previous or current syphilis and hepatitis C (Table 1) . There were no significant differences in BP, anthropometry, or serum lipid concentrations between groups. Differences in 10-year cardiovascular risk were commensurate with age. Recent recreational drug use was high in all 3 groups (.25% in the past 6 months). The most frequently reported recreational drugs were cannabis (16%), ketamine (15%), methamphetamine ("crystal meth", 13%), and amphetamine (13%). The number of HIV-positive patients receiving each antiretroviral therapy drug class did not differ between the older and younger groups [total number on nucleoside reverse transcriptase inhibitors, 138 (86.8%); nonnucleoside reverse transcriptase inhibitors, 82 (51.6%); †Recreational drugs included amphetamine ("speed"), cannabis, cocaine, ketamine, 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"), gamma-butyrolactone/gammahydroxybutyric acid (GBL/GHB), amyl nitrite ("poppers"), methamphetamine ("crystal meth"), and mephedrone.
‡Lipid Previous ocular conditions in the final sample included cytomegalovirus retinitis (n = 1), acanthamoeba infection resulting in a prosthesis on that side (n = 1), hyaline asteroidosis (n = 1), and cataracts (n = 2), all of which were in PLWH aged $50 years. An additional 17 patients (8.1%) with drusen were identified (11 PLWH aged $50 years, 1 PLWH aged ,50 years, and 5 HIV negative aged $50 years).
Comparison of Retinal Vascular Measurements Between Study Groups
Among the 211 participants, the mean AVR was 0.72 (SD 0.07), mean CRAE was 141 (SD 20.2), and mean CRVE was 197 (SD 28.1), with no differences on any variable between the 3 groups (P . 0.3), or between the 2 groups aged $50 years (HIV positive and HIV negative; P . 0.2) (Fig. 1) . The difference between the mean AVR in HIV-positive men aged $50 and the HIV-negative men of the same age was small: In bivariate models (Fig. 2, broken A multivariable model incorporating these variables, as well as study group, was then analyzed (Fig. 2, solid lines) . Systolic BP was included, but diastolic BP was omitted because of collinearity (systolic BP had the stronger association of the 2 variables). 
Association Between HIV-Related Factors and Retinal Vascular Measurements
In the analysis of only PLWH (Fig. 3) , adjusted for age group, there was an association between lower AVR and higher current CD4 + lymphocyte count (adjusted b 20.004 per +100 cells/mm 3 , 95% CI 20.008 to 0, P = 0.05), but no association with current CD8 + count, CD4:CD8 ratio, any specific antiretroviral drug or class, or any of the time spans analyzed (years on or off antiretroviral therapy, or total time since diagnosis).
DISCUSSION
In this study of 159 HIV-positive and 52 HIV-negative men, we found no association between HIV status and retinal vascular measurements. This is in keeping with the findings of a similar study in a South African population. 28 As expected, we found associations with hypertension and stroke history, as well as an association with recent recreational drug use. Within the group of PLWH, there was a smaller AVR in those with higher absolute CD4 + lymphocyte count, which may indicate the influence of immune activation, although CD4 + :CD8 + cell ratio was not associated. We did not observe any association between the duration of antiretroviral therapy and retinal arteriolar narrowing, 28 although this was observed in the South African study. PLWH receiving antiretroviral therapy in South Africa differ markedly in their clinical features from the UK HIV-positive population, and the health care systems providing HIV care have evolved in different ways, so there are several plausible explanations for the differences in our observations, including possible collinearity between age and duration of treatment in the South African patient sample.
Retinal photography with measurement of vascular caliber is widely used in epidemiological studies and clinical monitoring. Abnormal retinal diameters and qualitative features of retinopathy are associated with an increased risk of numerous conditions in middle-aged or older HIV-negative people, including neuroimaging features of SVD, cognitive impairment, stroke, cardiovascular disease, incident diabetes, metabolic syndrome, and all-cause mortality. [23] [24] [25] [26] [27] [34] [35] [36] [37] [38] [39] [40] In a large Dutch study (n = 5540), a decrease in AVR of 1 SD (0.06 in that study) was associated with a 14% increase in the risk of stroke. 40 This compares with an 8% increase in the risk conferred by a 10-mm Hg increase in systolic BP in white Americans and 24% increase in stroke risk from the same increase in BP in black Americans. 41 FIGURE 2. Factors associated with arterial-venous ratio, showing unadjusted (broken lines) and adjusted (solid lines) coefficients. Multivariable estimates and 95% CIs are shown. Leftward deflections in coefficient (negative values) indicate an association with lower AVR and more pathological change. Variables that were assessed in unadjusted models but are not shown here because P . 0.2 were body mass index, waist circumference, lipids, smoking status, self-report of previous ischemic heart disease, lifetime history of injection drug use, and hepatitis C antibody status. In studies using other measures of cerebral SVD, there is mixed evidence for whether the extent and severity of cerebrovascular disease is increased in PLWH. Earlier studies of mainly untreated HIV-positive individuals using older neuroimaging techniques found little evidence of an association between HIV and white matter hyperintensities of presumed vascular origin. 42, 43 Furthermore, an autopsy study of HIV-positive, hepatitis C virus-positive, and uninfected individuals found no association between cerebral SVD and HIV status. 22 More recently, 2 other studies measuring the total volume of white matter hyperintensities, a standard quantitative measure of cerebral SVD, 44 found no overall difference between HIV-positive and HIV-negative participants. 20, 21 But 2 recent neuroimaging studies that have found an association between HIV status and SVD include a recent Dutch study of men older than 45 years, in which the total volume of white matter hyperintensities was greater in PLWH than in well-matched HIV-negative study participants, 19 and a larger French study using the Fazekas and Schmidt neuroradiological rating scale, 45 which reported a higher prevalence of cerebral SVD in PLWH than in HIV-negative controls (unpublished conference abstract). 46 The control group in the latter study may not have been well matched, however, thus introducing bias.
Our study focused on a specific demographic group, which may limit the generalizability of our findings to other settings. We chose to restrict on the basis of ethnic group and sex to eliminate the well-described and powerful confounding effects of these variables on vascular disease markers; the study would likely have been insufficiently powered to perform sex and ethnicity subgroup analyses. We chose an older male cohort because such individuals are at greater risk of vascular disease, and we targeted the predominant demographic and transmission risk group (white men who have sex with men) attending our local clinics and living with HIV in the United Kingdom and many high-income settings. The study by Pathai et al 28 included a study sample that was different from our sample, being of younger age, entirely Xhosa ethnic group, and predominantly women, and they also found no association between HIV status and retinal vascular calibers. The strength of our study was that the HIV-negative controls had similar measured characteristics compared with the older HIV-positive sample, and their attendance for sexual health and HIV testing at the same centers as the HIV-positive groups should have reduced the effect of unmeasured confounders.
The study's sample size was smaller than planned, and the participants were in middle age and therefore at lower risk of cerebrovascular disease than an older-aged group. However, the difference observed between the HIV-positive and HIV-negative groups aged $50 was very small compared with the overall distribution of values, and despite the small sample, the evidence for there being no true difference in retinal calibers on the basis of HIV status is strong.
The results of this study contribute to the accumulated evidence so far in this field. In summary, this evidence does not consistently find HIV to be a risk factor for cerebral SVD. Of the PLWH aged $50, 24% had a 10-year risk of cardiovascular disease (Framingham model) of above 10% (the threshold above which the UK National Institute for Health and Care Excellence recommends statin therapy for primary prevention). 47 Our findings do not diminish the need for assessment and optimization of individual patients' cardiovascular risks.
